Summary & Overview
HCPCS Level II J1554: Immune Globulin (asceniv) 500 mg Injection
HCPCS Level II code J1554 denotes a 500 mg injection of immune globulin (asceniv). This product-specific code matters nationally for hospitals, infusion centers, and physician practices that administer immune globulin therapies because it identifies the drug and unit quantity for billing, inventory, and payer coverage determinations. Accurate use of J1554 supports clinical documentation, claims adjudication, and tracking of biologic utilization.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for asceniv administration, expected sites of service, and common billing considerations tied to a product-specific HCPCS Level II code. The publication outlines benchmarks and reimbursement patterns where available, highlights policy updates relevant to HCPCS drug coding, and explains how J1554 fits into infusion and injectable therapy workflows. It also addresses typical documentation elements required for drug-specific HCPCS coding and offers guidance on navigating payer coverage policies. Where input data is incomplete, the report notes that specific fields were not provided.
Billing Code Overview
HCPCS Level II code J1554 represents an injection of immune globulin (asceniv), 500 mg. This code describes a single unit of the specified immune globulin product administered by injection.
Service type: Parenteral therapeutic infusion or injection of an immune globulin product.
Typical site of service: Administration typically occurs in outpatient infusion centers, physician offices, or hospital outpatient departments depending on clinical need and payer rules.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult with primary humoral immunodeficiency presents to an outpatient infusion center for immune globulin replacement therapy using asceniv (recombinant hyaluronidase-facilitated subcutaneous human immunoglobulin). The patient arrives after nursing triage confirms recent weight, vital signs, and review of recent laboratory results including IgG trough levels. The infusion nurse reviews indication, verifies the prescription for J1554 (injection, immune globulin (asceniv), 500 mg), confirms venous or subcutaneous access based on product formulation and dosing plan, and prepares product dosing individualized to the patient’s weight and prior tolerability. The workflow includes pre-medication assessment (antipyretics, antihistamines if previously required), verification of consent and adverse reaction plan, administration per product-specific rate escalations, monitoring during and for at least 30–60 minutes post-infusion for infusion reactions, documentation of lot number and units administered, and scheduling of the next maintenance dose.
Typical site of service is an outpatient infusion center, ambulatory infusion clinic, or physician office with infusion services. In some cases, home infusion may be arranged with a certified home infusion provider and appropriate documentation of training and monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — full service |